Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,166.9
-

 

  • STI Straits Times Index
    3,166.9
    -
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,494.6
    -18.3 (-1.21%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,961.0
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,397.4
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,283.6
    -
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,070.0
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,329.7M
  • Value: 1,564.3M
  • Rise: 137
  • Fall: 185
  • Unch: 438

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.115+0.007
Hong Lai Huat0.107+0.003
RH PetroGas0.175-0.007
Singtel2.270-0.010
Shen Yao0.006-0.001
Golden Agri-Res0.230-0.005
CapLand IntCom T2.150+0.010
Genting Sing0.810-0.010
Mercurius0.061-
GKE0.146-0.007

World Indices

World Indices
Name Last Change
Nasdaq 14,672.7 -105.6
HSI 25,961.0
HSCEI 9,233.2
Jakarta 6,070.0
Nikkei 225 27,283.6
SSE Comp 3,397.4
Shanghai A 3,560.7
Shanghai B 254.0
KOSPI 3,202.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Y-MABS THERAPEUTICS INC Y-MABS THERAPEUTICS
Updated on 30 Jul 2021 (End of trading day)
Last (USD): 33.100 Change: -0.400 High: 33.385 Remarks: -
Change (%): -1.19 Low: 32.230
Open 33.330 Yesterday's Close 33.5
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 98,230 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -2.73888 Trailing EPS (USD) e -1.37120 NAV (USD) b 5.7886
PE a - Trailing PE f - Price / NAV b 5.7181
Dividend (USD) d - Cash In Hand (USD) g 5.7898 Issued & Paid-up Shares c 43,571,400
Dividend Yield (%) d - Price / Cash In Hand g 5.717 Treasury Shares h -
Market Cap (M) 1,442.213 Enterprise Value (M) 1,193.428
Piotroski F Score 0 Exchange Code YMAB Par Value ( $ ) n.a.
52 Weeks Volatility (%) 55.37 Free Float (%) 79.1
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 11 May 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Sep 2018.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Y-MABS THERAPEUTICS INC NASDAQ 1,442.213 - - 5.7181 -
Industry Pharmaceuticals: Major NASDAQ 2,391.520 87.484 91.614 3.4041 0.026
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 177,342.685 55.061 54.624 - 2.028
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 130,276.652 9.281 36.392 - 2.594
Local Peer ROYALTY PHARMA PLC NASDAQ 23,191.678 23.785 23.840 4.7502 0.502
Local Peer VIATRIS INC NASDAQ 17,005.846 - - 0.7941 -
Local Peer REPLIGEN CORP NASDAQ 13,507.898 225.409 135.170 8.4263 -
Local Peer CUREVAC NV NASDAQ 9,173.197 - - - -
Local Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 7,267.207 - - 7.3797 -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 6,352.760 - - 6.7328 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 6,223.515 - - 30.1436 -
Local Peer I MAB SPON ADS EACH REP 2.3 ORD SHS NASDAQ 6,009.240 88.078 88.078 6.9838 -
Local Peer APELLIS PHARMACEUTICALS INC NASDAQ 5,150.990 - - 99.7195 -
Local Peer REATA PHARMACEUTICALS INC NASDAQ 4,545.977 - - 12.3086 -
Other Local Peers ALLAKOS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ERASCA INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), PETIQ INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), GH RESEARCH PLC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ESSA PHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ANNEXON INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), EVOLUS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), PHARVARIS NV (NASDAQ), VERU INC (NASDAQ), AC IMMUNE SA (NASDAQ), CLENE INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), XOMA CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), DURECT CORP (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), 89BIO INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), NEXIMMUNE INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), VINCERX PHARMA INC (NASDAQ), IMMUNIC INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), OBSEVA SA (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), GENPREX INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), NOVAN INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), PROPHASE LABS INC (NASDAQ), GALECTO INC (NASDAQ), MEDIWOUND LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), GRAYBUG VISION INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), MANNATECH INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), PAINREFORM LTD (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ)
Global Peer JOHNSON & JOHNSON NYSE 453,313.056 30.808 25.514 6.5150 2.311
Global Peer PFIZER INC NYSE 239,637.109 24.921 18.116 - 3.554
Global Peer ELI LILLY AND COMPANY NYSE 233,522.831 37.703 38.330 33.8505 1.213
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 224,916.064 27.698 25.007 4.1619 2.086
Global Peer ABBVIE INC NYSE 205,411.386 45.086 40.403 14.9827 4.159
Global Peer MERCK & CO INC NYSE 194,639.452 27.542 48.346 - 3.224
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 164,139.056 25.472 24.416 17.7561 1.453
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,814.606 - - 4.0973 2.738
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 100,985.818 13.698 17.026 4.7540 5.155
Global Peer WUXI APPTEC HKEx 510,950.397 153.950 107.255 12.2061 0.203
Other Global Peers TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), SINOPHARM (HKEx), HUTCHMED (HKEx), ORGANON & CO (NYSE), REMEGEN-B (HKEx), HYGEIA HEALTH (HKEx), JUNSHI BIO (HKEx), SH PHARMA (HKEx), AKESO-B (HKEx), CMS (HKEx), INNOCARE-B (HKEx), BAIYUNSHAN PH (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), CHINARES PHARMA (HKEx), SIMCERE PHARMA (HKEx), TRAD CHI MED (HKEx), CHINAGRANDPHARM (HKEx), EVEREST MED-B (HKEx), HENLIUS (HKEx), CSTONE PHARMA-B (HKEx), CARSGEN-B (HKEx), SSY GROUP (HKEx), HEPALINK (HKEx), OCUMENSION-B (HKEx), ADC THERAPEUTICS SA (NYSE), AMNEAL PHARMACEUTICALS INC (NYSE), ZYMEWORKS INC (NYSE), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), UNITED LAB (HKEx), ANTENGENE-B (HKEx), TONGRENTANGCM (HKEx), IMMUNOTECH-B (HKEx), Kimia Farma Tbk. (IDX), CKLIFE SCIENCES (HKEx), SCICLONE PHARMA (HKEx), SHINEWAY PHARM (HKEx), ZHAOKE OPHTH-B (HKEx), HUA MEDICINE-B (HKEx), Soho Global Health Tbk. (IDX), STARPHARMA HOLDINGS LIMITED (ASX), IGBB (Bursa), PYC THERAPEUTICS LIMITED (ASX), RACE ONCOLOGY LTD (ASX), DAWNRAYS PHARMA (HKEx), AFT PHARMACEUTICALS LTD (ASX), TOT BIOPHARM-B (HKEx), BSTEAD (Bursa), ANNOVIS BIO INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), PHARMA (Bursa), FUSEN PHARM (HKEx), LANNETT CO INC (NYSE), IP (SET), CH BIOTECH SER (HKEx), ZHONGZHIPHARM (HKEx), NOXOPHARM LTD (ASX), IX Biopharma (SGX), RECCE PHARMACEUTICALS LTD (ASX), Merck Tbk. (IDX), CRESO PHARMA LTD (ASX), NEW RAY MEDIC (HKEx), CHARMACY PHAR (HKEx), KOTRA (Bursa), NC HEALTHCARE (HKEx), Phapros Tbk. (IDX), PAK FAH YEOW (HKEx), Hyphens Pharma (SGX), NOVA (Bursa), INVION LTD (ASX), MODERN CHI MED (HKEx), BIOHLDG (Bursa), EXOPHARM LTD (ASX), NEP INTERLONG (HKEx), AGEX THERAPEUTICS INC (NYSE American), MEDLAB CLINICAL LIMITED (ASX), WAI YUEN TONG (HKEx), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), PURAPHARM (HKEx), TIMBER PHARMACEUTICALS INC (NYSE American), SANAI HEALTH GP (HKEx), EXTRAWELL PHAR (HKEx), PHARMAXIS (ASX), JCT (SET), SUNZEN (Bursa), TALI DIGITAL LIMITED (ASX), ONCOSIL MEDICAL LIMITED (ASX), IMMURON LIMITED (ASX), ACRUX (ASX), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --2.230
-6.31 %
10 Days -+1.440
+4.55 %
20 Days --1.500
-4.34 %
Medium Term Return 3 Months -+3.030
+10.08 %
6 Months --8.910
-21.21 %
1 Year --2.030
-5.78 %
Long Term Return 2 Years -+9.880
+42.55 %
Annualised Return Annualised --
+19.39 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 24.775 - 55.215 Change From 1 Year Low +8.325 % Change From 1 Year Low (%) +33.60
Change From 1 Year High -22.115 % Change From 1 Year High (%) -40.05
2 Years Range 14.160 - 55.215 Change From 2 Years Low +18.940 % Change From 2 Years Low (%) +133.76
Change From 2 Years High -22.115 % Change From 2 Years High (%) -40.05
5 Years Range 14.160 - 55.215 Change From 5 Years Low +18.940 % Change From 5 Years Low (%) +133.76
Change From 5 Years High -22.115 % Change From 5 Years High (%) -40.05
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
30 Jul 2021 33.330 33.385 32.230 33.100 98,230 -
29 Jul 2021 34.190 35.670 33.240 33.500 186,871 -
28 Jul 2021 32.500 34.160 31.960 34.040 160,049 -
27 Jul 2021 32.510 33.190 30.950 32.450 255,127 -
26 Jul 2021 35.440 35.450 32.290 32.730 339,970 -
23 Jul 2021 34.700 35.630 33.980 35.330 271,266 -
22 Jul 2021 34.500 35.780 33.890 34.650 397,828 -
21 Jul 2021 32.860 35.309 32.360 35.050 390,361 -
20 Jul 2021 31.190 33.100 31.190 32.740 303,067 -
19 Jul 2021 31.100 31.875 30.860 31.150 147,829 -
16 Jul 2021 31.470 32.680 31.250 31.660 88,085 -
15 Jul 2021 30.490 31.550 30.360 31.170 153,542 -
14 Jul 2021 31.610 32.500 30.560 30.730 139,744 -
13 Jul 2021 32.490 32.490 31.000 31.860 134,437 -
12 Jul 2021 32.950 33.305 32.110 32.830 100,959 -
09 Jul 2021 31.920 33.030 31.000 32.940 91,618 -
08 Jul 2021 31.880 32.440 31.010 31.620 177,822 -
07 Jul 2021 32.590 32.980 31.315 31.890 137,894 -
06 Jul 2021 34.150 34.180 32.160 32.570 159,496 -
02 Jul 2021 35.350 35.350 33.710 34.600 109,345 -
01 Jul 2021 33.880 35.200 33.640 35.130 153,290 -
30 Jun 2021 33.720 34.270 33.450 33.800 101,973 -
Summary
Current 2 Weeks
(19 Jul 2021 to 30 Jul 2021)
31.100 35.780 30.860 33.100 2,550,598 -
Previous 2 Weeks
(02 Jul 2021 to 16 Jul 2021)
35.350 35.780 30.860 31.660 1,292,942 -
4 Weeks from
(04 Jun 2021 to 01 Jul 2021)
34.180 35.780 30.860 35.130 5,973,567 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Result